Search This Blog

Wednesday, October 12, 2022

Maternity care in the U.S. is in crisis. It’s time to call the midwife

 After pushing for several hours, my patient looks exhausted but happy, clutching her seconds-old newborn to her chest. As I help her put her baby to breast for the first time, she isn’t thinking about anything other than the tiny human blinking up at her.

As well she shouldn’t.

She doesn’t know that this birth would have happened by C-section at most American hospitals, something that would have put her at risk for a host of complications and virtually guaranteed that any future births would also be by C-section. But I do.

As a certified nurse-midwife, I know that my presence, patience, and encouragement during her labor probably made the difference between a vaginal birth and a C-section. A recent study linked midwifery care from hospital-based midwives like me to 30% to 40% lower rates of C-section for low-risk women.

In the United States, about 32% of births occur by C-section, even though the World Health Organization recommends rates not exceed 10% to 15% for optimal maternal and neonatal outcomes. But C-section rates are not the only area in which the U.S. is underperforming.

At 24 deaths per 100,000 live births, its maternal mortality rate is more similar to that of Iran than of economic peers like the United Kingdom or Germany. Preterm birth, a major cause of infant death and lifelong disability, occurs in 1 of 10 births. Seven million women live in maternity care deserts with minimal access to care. Yet with the average cost of maternity care at nearly $19,000, the U.S. spends far more on maternity care than countries with much better outcomes.

The reasons for America’s high-cost, low-quality maternity care are complex. But one rarely acknowledged difference between the U.S. and countries with better outcomes is that they use more midwives. The U.S. has a similar number of OB-GYNs per 1,000 births compared to countries like Britain, the Netherlands, and France. But in those countries, midwives are an integral part of the health care system, outnumbering OB-GYNs 3 to 1.

Why does this model work? A strong midwifery workforce frees up physicians to concentrate on high-risk pregnancies while offering lower-risk pregnant people more personalized care with longer visits and increased psychosocial support, which are typical of the midwifery model of care.

Just as midwifery has been successful abroad, U.S. states with greater midwifery integration into their health care systems have better outcomes, including lower rates of C-sections, preterm births, and neonatal deaths.

So why is the U.S. sitting on a solution that could clearly benefit childbearing families? A host of cultural and historic reasons account for the continued marginalization of midwifery in the U.S.

Sometimes I envy my colleagues across the Atlantic, where “midwife” is a household name that garners respect and admiration. Midwifery is widely accepted by the British public and medical system, with 43 midwives per 1,000 births compared to America’s 4 per 1,000. It barely made the news that Duchess Kate Middleton delivered her babies with midwives. Rather, The Economist mused that Kate’s delivery in a private, luxury maternity suite cost less than the average vaginal birth in the United States.

In the U.S., midwives like me face a different reality. I am frequently asked to explain the difference between a midwife — a licensed health care provider — and a doula — a counselor who provides emotional support and guidance through the childbearing process. I have to defend my education and credentials to people who assume I have no formal training, though becoming a certified nurse-midwife requires a master’s degree, hundreds of hours of clinical training, and board certification.

Midwifery is often written off by the American public as a fringe choice for women who eschew pain medication in labor and plan to give birth at home. While it’s true that most home births are attended by midwives — usually certified professional midwives, who have extensive apprenticeship training — the vast majority of midwife-attended births occur in hospitals, with certified nurse-midwives like me. And women don’t have to choose between a midwife and an epidural. I’ve attended births by people who labored in a tub with aromatherapy and soft music in the background, and by those who got epidurals and watched the Green Bay Packers game.

American midwifery’s public relations problems are deeply rooted in history. A campaign by the American Medical Association in the early 1900’s discredited midwives as quacks. Doctors lobbied to remove midwifery training programs and pass laws making midwifery illegal. Joseph DeLee, an influential early 20th century obstetrician, called midwives a “relic of barbarism.” Sexist and racist attacks painted midwives as dirty, uneducated, and dangerous. By the 1940’s midwifery was virtually eradicated in the United States.

It was preserved, however, in Black communities, whose members were not allowed in many hospitals during segregation. The African American midwife Margaret Charles Smith, whose career attending home births in Alabama spanned several decades, wrote in her autobiography about Black patients being denied access to the hospital even when they had life-threatening complications. Ironically, she was later forbidden from attending home births after it was made illegal. Highly skilled midwives like Smith were forced out of business, leaving Black communities without their traditional caregivers.

Discrimination against midwives is still baked into health care policy. It limits the number of midwives and hamstrings the efforts of existing midwives.

Midwifery training programs are few and underfunded, receiving just a fraction of the funding that medical schools and residency programs get. Universities with midwifery programs mostly depend on volunteer midwives to train students during in-person clinical work without reimbursement, thus limiting the supply of willing preceptors.

Recent interest in increasing capacity for midwifery education led to the Midwives for Moms Act, which was introduced into Congress in 2021. It would provide funding to create or expand education programs with an emphasis on restoring midwifery to underserved areas. Passing this bill is a must if the U.S. is to begin addressing its dearth of midwives.

In my home state and many others, a midwife’s ability to practice legally is contingent upon a physician’s willingness to sign a collaboration agreement. An obvious restraint of trade, laws like this give physicians an opportunity to intentionally exclude midwives from the workforce due to fears about competition. They also create burdensome requirements and potential liability for physicians who would otherwise be willing to work with midwives, disincentivizing collaboration.

Overcoming decades of bias against midwifery won’t be easy, but I see a tipping point on the horizon. At 1 in 10, the number of midwife-attended births in the U.S. is the highest it has been in decades. Women are increasingly choosing midwives, putting pressure on health care systems to respond to the demand by hiring more of them. Healthcare administrators may also notice that, at $116,892 compared to $302,301, the yearly cost of employing a certified nurse-midwife is significantly cheaper than employing an OB-GYN.

Midwifery care cuts cost, improves outcomes, and increases patient satisfaction. The next logical step is to create policies that increase the number of midwives and address barriers to midwifery practice.

I’d love to live in a country where my profession is better understood and more respected. But it’s really not about me. The U.S. needs more midwives because the nation’s subpar birth outcomes and excessive costs are evidence that pregnant people are not getting the care they need most while health care dollars go to waste.

The country has already waited too long: It’s time to call the midwife.

Ann Ledbetter is a certified nurse-midwife at Sixteenth Street Community Health Centers in Milwaukee, Wis., and a member of Wisconsin’s Maternal Mortality Review Team.

https://www.statnews.com/2022/10/12/maternity-care-in-the-u-s-is-in-crisis-its-time-to-call-the-midwife/

Hospitals are hiding prices from patients, advocacy report says

 

  • Some large hospitals are still not posting their complete price lists as required by federal transparency rules, a new analysis by PatientRightsAdvocate.org found. A comparison of price data for seven hospitals in Florida and Texas, owned by two major health systems, to corresponding insurance plan data revealed the omissions in the hospital files, the organization said.
  • The analysis looked at price disclosures from two hospitals owned by Ascension Health and five owned by HCA Healthcare. The data was cross-referenced with newly released information on prices negotiated with insurers including Blue Cross Blue Shield, UnitedHealthcare and Cigna.
  • Ascension, in an emailed statement, said it is complying with the CMS rule and has gone beyond it by offering consumers tools to estimate costs and provide feedback. “We’re proud to be a leader in price transparency,” the health system said. In a statement, HCA Healthcare said that it had implemented federal transparency requirements in January 2021 and currently provides a patient payment estimator on its website in addition to posting third-party contracted rates in machine-readable file formats
The hospital price transparency rule, which took effect in January 2021, requires hospitals to publish machine-readable price lists and display rates for medical services in a format that allows consumers to comparison shop. Insurers are now required to disclose rates they negotiate with providers.

In the first year after the hospital rule, studies evaluating compliance with the regulation, including one by Patient Rights Advocatefound efforts lacking. In February, the nonprofit said only 14.3% of hospitals were compliant with disclosure requirements. CMS itself said its initial analysis “strongly suggests there is sub-optimal compliance” with the rule, and the agency increased fines for non-compliant hospitals.

The flood of information from insurers released in July, 18 months after the hospital rule, gave researchers a much greater pool of data for assessing transparency efforts. Cynthia Fisher, chairman of PatientRightsAdvocate.org, called her group’s new report the “tip of the iceberg” of what publicly disclosed data files mandated by the the new regulations will reveal.

The data obtained from machine-readable files showed multiple instances where prices for services were omitted from the hospitals’ lists, the advocacy group said. Some prices in insurance company files appear with an “N/A” or are blank in the corresponding hospital price lists. “This concrete evidence from the insurance files demonstrates that real prices exist and hospitals are flouting the hospital price transparency rule,” the report said.

The American Hospital Association has taken issue with outside studies it contends are misrepresenting the price disclosure rules. The group, which fought an unsuccessful legal battle to block the regulation, maintains hospitals are working to implement price transparency policies and develop tools to help patients understand costs.

Compiling large machine-readable files has proven more difficult, but outside assessments have ignored CMS guidance allowing a blank cell to be left when an individual negotiated rate does not exist due to services being bundled, the hospital lobby said.

https://www.healthcaredive.com/news/Patient-Rights-Advocate-price-transparency-HCA-Ascension/633666/

Social Security Payments Are Going Up a Lot, But Maybe Not Enough

 Social Security recipients will know the amount of their higher payments for 2023 after an announcement is made Thursday, Oct. 13.

Estimates suggest the Social Security Administration will put the increase of the new cost-of-living adjustment (COLA) at nearly 9%. That would be the largest hike since the most recent inflationary period more severe than the current one resulted in an increase of 11.2% in 1981.

At a 9% increase, a near-average Social Security check for $1,600 would be adjusted to $1,744.

In addition to the short-term benefit, the increase is important for the long term as well. That's because any future changes to COLA will be based on the new, higher number. So it's a relatively permanent boost.

But it's really the only way to help beneficiaries try to keep up with rising costs. As interest rates rise to fight inflation, other costs involving loans and credit cards will also continue to expand. 

It's not only senior citizens whose benefits will improve with these changes. Many people with disabilities, and an estimated 4 million children whose parents are retired, deceased or disabled will receive the increased payments as well. 

Controversy Over Calculating COLAs

The Senior Citizens League (TSCL) believes that COLA is being calculated incorrectly and to the disadvantage of seniors.

"According to TSCL’s research, Social Security benefits have lost over thirty percent of their purchasing power since 2000 due in large part to inadequate COLAs and rising health care costs," the organization writes. "To address this growing issue, TSCL urges Congress to adopt legislation that would base the COLA on an inflation index specifically for seniors, like the Consumer Price Index for the Elderly (CPI-E)."

The COLA calculation for Social Security payments is currently based on the Consumer Price Index for Urban Wage Earners and Clerical Workers (CPI-W). 

"The index that is currently used to measure inflation," TSCL continues, "underestimates the inflation that Social Security beneficiaries experience since it does not give enough weight to expenses like health care or housing costs."

The senior advocacy group says it supports legislation such as the CPI-E Act, the Guaranteed 3% COLA Act, and the Seniors’ Security Act. It also encourages efforts to provide beneficiaries an increase in benefits to help compensate for years of what it calls low COLAs.

Some CPI Variant Specifics

The Bureau of Labor Statistics describes the CPI-W as a "specialized index and seeks to track retail prices as they affect urban hourly wage earners and clerical workers. It encompasses about 32 percent of the United States' population."

The CPI-W is a subset of the more general CPI-U. The Consumer Price Index for All Urban Consumers (CPI-U) is a measure of change in prices paid by urban consumers for a wide range of consumer goods and services. It applies to about 87% of the population.

The Consumer Price Index for the Elderly (CPI-E) uses the same data as the CPI-W, but it uses expenses for households including people 62 years of age or older. So it more specifically is aimed at the demographic mostly affected by Social Security benefit adjustments.

The CPI-E covers a population about one-third the size of the CPI-U and is referred to often as experimental.

https://www.thestreet.com/investing/social-security-payments-are-going-up-a-lot-but-maybe-not-enough

Nevro: FDA OKs Spinal Cord Stimulation System for Treatment of Chronic Pain

 Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the Senza HFX iQ spinal cord stimulation (SCS) system.

Senza HFX iQ is the first and only Artificial Intelligence-based SCS system that learns from patients. It was developed to address the variability in pain from patient to patient and to help patients optimize and maintain long-term pain relief and improved quality of life. The Senza HFX iQ system is comprised of the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger and HFX App and will launch with algorithms specifically for treating chronic back and leg pain,

https://www.marketscreener.com/quote/stock/NEVRO-CORP-18445411/news/Nevro-Announces-FDA-Approval-of-HFX-iQ-trade-Spinal-Cord-Stimulation-System-to-Personalize-the-Trea-41994085/

Biomea Fusion Corporate Presentation

This is an excerpt of the original content. To continue reading it, access the original document here.

Toothbrushing key to preventing pneumonia in ICU patients, leads to US guideline changes

 A study led by researchers at the University of Toronto and its partner hospitals has contributed to a major change in American guidelines for pneumonia prevention among ICU patients on mechanical ventilators.

The study, published late last year in Intensive Care Medicine, was among the first in the world to show that the oral rinse should be discontinued and oral care, including tooth brushing, should be implemented instead.

The updated U.S. guideline governs care in all U.S. hospitals and has been approved by the Centers for Disease Control and Prevention (CDC).

"To see the connection between  and systemic health bolstered by our study findings in the guideline is a long-awaited change," says Craig Dale, a nurse scientist in the ICU at Sunnybrook Health Sciences Center and an associate professor in U of T's Lawrence S. Bloomberg Faculty of Nursing.

"Speaking on behalf of our research team, we are quite proud of the innovation our work proposes. It also shows how Canadian research can lead to a change in international practice."

Pneumonia is a significant risk to patients who pass through the hospital and especially the ICU. Patients may be exposed to many things that change the microbiome in their mouth, including medications that are very drying, restrictions on eating and drinking and lack of oral care. The tube used for ventilating can also be a conduit for bacteria to enter the lungs, which leads to pneumonia.

"When there is a large overgrowth of bacteria in the mouth, it can be aspirated from the mouth into the lungs, especially when patients are lying on their backs," says Dale.

The use of an antimicrobial oral rinse has for many years been thought to be successful in preventing pneumonia in the ICU, but over the last eight years a series of systematic reviews began to show an excess mortality signal.

"It appeared as though oral rinse exposure could be contributing to the death of patients in the ICU," says Dale. "It also appeared that the oral rinse was not doing what it was supposed to do—which was prevent pneumonia."

To further investigate if this signal was true, Dale and his co-investigator Brian Cuthbertson, also of Sunnybrook Health Sciences Center and a professor in the Temerty Faculty of Medicine, designed what's known as a de-adoption trial in collaboration with hospitals and ICU staff across the Toronto Academic Health Sciences Network (TAHSN). The study would swap out the use of the oral rinse but preserve oral health with an oral care bundle that included toothbrushing and moisturizing the lips and mouths of patients regularly.

The study evaluated outcomes including changes in ICU mortality, respiratory infection, time spent on the ventilator and patient comfort, and concluded that the oral rinse was not needed to prevent pneumonia. Instead, the oral care bundle designed by Dale and his fellow researchers performed just as well as the rinse and appeared to do a better job in the promotion of oral health in patients overall.

"We saw no effect on ICU mortality and other patient-centered outcomes when comparing the antimicrobial rinse and an oral care bundle. As patients should have their teeth brushed anyway, we saw there was no need for the addition of the mouth rinse, which may have side-effects for patients," says Dale.

The value of comprehensive oral care for ICU patients is something Dale says cannot be understated. Not only does it safeguard patients from harm, but it can also help them resume speech, swallowing and a regular diet more quickly once they are no longer ventilated.

Nurses, he adds, continue to play a significant role in delivering pneumonia prevention at the bedside. With the introduction of oral care bundles, the role of nurses in implementing this practice change is even more important.

"Oral care involving tooth brushing, moisturizing the mouth and deep suctioning requires a different skillset than simply applying a topical rinse. This proposed change is a complex intervention for very sick patients with tubes and fluctuating levels of consciousness and abilities to co-operate," says Dale. "De-adoption of this long-held practice really puts the onus on nurses to pick up the gauntlet again and make sure we can deliver this care to protect patients from poor outcomes."

While  prevention guidelines in the U.S. have been updated, citing evidence from Dale's study, the guidelines for Canada have yet to be changed. Nonetheless, introducing toothbrushing as an essential, rather than optional, component of care for patients admitted to hospital and ICU is the first major change in such guidance in several decades.

Practice change, particularly in an ICU setting, is difficult to accomplish, Dale acknowledges, but he says the new guideline is a step forward in providing better care for patients and recognizing the often-ignored connection between oral and systemic health. A lot of work remains to be done to raise awareness of the important changes to the American guideline, he says.

"Providing better oral care will put hospitalized patients in the best position to recover from illness and this is something that falls into the remit of nursing."


Explore further

Why good oral health is more than a beautiful smile

More information: Craig M. Dale et al, Effect of oral chlorhexidine de-adoption and implementation of an oral care bundle on mortality for mechanically ventilated patients in the intensive care unit (CHORAL): a multi-center stepped wedge cluster-randomized controlled trial, Intensive Care Medicine (2021). DOI: 10.1007/s00134-021-06475-2
https://medicalxpress.com/news/2022-10-toothbrushing-key-pneumonia-icu-patients.html

Paxlovid may interact with common heart medications

 Heart disease patients with symptomatic COVID-19 are often treated with nirmatrelvir-ritonavir (Paxlovid) to prevent progression to severe disease; however, it can interact with some previously prescribed medications. A review paper published today in the Journal of the American College of Cardiology examines the potential drug-drug interactions (DDIs) between Paxlovid and commonly used cardiovascular medications, as well as potential options to mitigate severe adverse effects.

"Awareness of the presence of drug-drug interactions of Paxlovid with common cardiovascular drugs is key. System-level interventions by integrating drug-drug interactions into electronic medical records could help avoid related adverse events," said Sarju Ganatra, MD, director of the cardio-oncology program at Lahey Hospital and Medical Center in Burlington, Massachusetts, and the senior author of the review.

"The prescription of Paxlovid could be incorporated into an order set, which allows physicians, whether it be  or cardiology providers, to consciously rule out any contraindications to the co-administration of Paxlovid. Consultation with other members of the health care team, particularly pharmacists, can prove to be extremely valuable. However, a health care provider's fundamental understanding of the drug-drug interactions with  is key."

Paxlovid received emergency use authorization from the U.S. Food and Drug Administration in December 2021 as an oral antiviral agent for the treatment of symptomatic, non-hospitalized adults with mild to moderate COVID-19 infection who are at high risk for progression to severe disease. Patients with heart disease and other risk factors, including diabetes, , chronic kidney disease and smoking make up a large portion of the high-risk population for whom Paxlovid is beneficial.

According to the authors, Paxlovid has been shown to be very effective in patients with existing heart disease, but it has significant DDIs with commonly used cardiovascular medications, highlighting the importance for all clinicians to be familiar with these DDIs. As there is limited clinical information regarding DDI-related adverse events, the authors used existing knowledge and data regarding how therapies like Paxlovid typically react with other medications to provide guidance regarding potential interactions and the associated likely consequences based on the degree of interaction.

Dr. Ganatra discusses the potential drug-drug interactions between Paxlovid and commonly used cardiovascular medications. Credit: American College of Cardiology

The review provides an in-depth overview of a variety of cardiovascular medications used to treat many forms of heart disease. Five of the most important cardiovascular drug interactions with Paxlovid to be aware of include:

  • Anti-arrhythmic agents

    • Anti-arrhythmic agents are used to manage abnormal heart rhythm. Many of these drugs are metabolized in a way that increases plasma levels when co-administered with Paxlovid. While it may be possible to start Paxlovid after 2-2.5-day temporary discontinuation of the anti-arrhythmic agents, this may not be feasible from a practical standpoint. Clinicians are advised to consider alternative COVID-19 therapies and avoid co-administration of these agents with Paxlovid. Sotalol, another anti-arrhythmic agent, is renally cleared and does not interact with Paxlovid.
    • Antiplatelet agents and anticoagulants
    • Antiplatelet agents are used for the treatment of coronary artery disease, particularly if a patient has received a stent. Aspirin and prasugrel are safe to co-administer with Paxlovid. There is an increased risk of blood clots when Paxlovid is given alongside clopidogrel and an increased risk of bleeding when given with ticagrelor. When possible, these agents should be switched to prasugrel. If patients have contraindication to taking prasugrel, then co-administration of Paxlovid should be avoided and alternative COVID-19 therapies should be considered.
    • Anticoagulants (blood thinners used to treat or prevent blood clots) such as warfarin may be co-administered with Paxlovid but require close monitoring of clotting factors in bloodwork. The plasma levels of all direct oral anticoagulants increase when co-administered with Paxlovid, therefore dose adjustment or temporary discontinuation and use of alternative  may be required.
  • Certain statins

    • Co-administration of simvastatin or lovastatin with Paxlovid can lead to increased plasma levels and subsequent muscle weakness (myopathy) and rhabdomyolysis, a condition in which the breakdown of muscle tissue releases a damaging protein into the bloodstream. These agents should be stopped prior to initiation of Paxlovid. A dose reduction of atorvastatin and rosuvastatin is reasonable when co-administered with Paxlovid. The other  are considered safe when given along with Paxlovid.
  • Ranolazine

    • Plasma concentration of ranolazine, used to treat angina and other heart-related chest pain, is exponentially increased in the presence of CPY450 inhibitors like Paxlovid, thereby increasing the risk of clinically significant QT prolongation and torsade de pointes (a type of arrhythmia). Co-administration of Paxlovid is therefore contraindicated. Temporary discontinuation of  is advised if prescribing Paxlovid.
  • Immunosuppressive agents

    • The  of immunosuppressive agents prescribed for patients who have undergone heart transplantation exponentially rise to toxic levels when co-administered with Paxlovid. Temporary reduction of dosing of immunosuppressive agents would require frequent monitoring and be logistically difficult. Therefore, alternative COVID-19 therapies should be considered in these patients.

The authors conclude awareness and availability of other COVID-19 therapies enable clinicians to offer alternative treatment options to patients who are unable to take Paxlovid due to DDIs.


Explore further

SARS-CoV-2-linked hospitalization, ED encounters rare after Paxlovid

More information: Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week, Journal of the American College of Cardiology (2022). DOI: 10.1016/j.jacc.2022.08.800
https://medicalxpress.com/news/2022-10-covid-drug-paxlovid-interact-common.html